Mental Retardation: Developing Pharmacotherapies / Edition 1

Mental Retardation: Developing Pharmacotherapies / Edition 1

by John J. Ratey
     
 

ISBN-10: 0880484527

ISBN-13: 9780880484527

Pub. Date: 07/28/1991

Publisher: American Psychiatric Publishing, Incorporated

In the last few years, psychiatry in the field of mental retardation has begun to reexamine the subtler effects of the medications it employs. This volume is designed to further our understanding of the pharmacologic treatability of the mental illnesses that individuals with mental retardation often display.

The book shows how mentally retarded patients can

Overview

In the last few years, psychiatry in the field of mental retardation has begun to reexamine the subtler effects of the medications it employs. This volume is designed to further our understanding of the pharmacologic treatability of the mental illnesses that individuals with mental retardation often display.

The book shows how mentally retarded patients can benefit from pharmacological interventions that are part of a multisystems approach to treatment, the aim of which is to maintain or increase the cognitive functioning of the individual. In this respect, pharmacologic and polypharmacologic approaches are sought to provide more efficacious, less toxic treatment regimens for these patients. New insights into the nature of neurological disturbance in mental retardation are presented, and the book offers a practical guide to the treatment of developmentally disabled people.

American Psychiatric Publishing

Product Details

ISBN-13:
9780880484527
Publisher:
American Psychiatric Publishing, Incorporated
Publication date:
07/28/1991
Series:
Progress in Psychiatry Series, #32
Edition description:
1st ed
Pages:
174
Product dimensions:
5.70(w) x 8.50(h) x 0.40(d)
Age Range:
18 Years

Table of Contents

Neuropsychiatry and mental retardation. Mental illness in the mentally retarded: diagnostic clarity as a prelude to psychopharmacological interventions. TMS: a system for prevention and control. ?-blockers as primary treatment for aggression and self-injury in the developmentally disabled. Use of anticonvulsant agents for treatment of neuropsychiatric disorders in the developmentally disabled. Effects of opioid receptor antagonists in treatment of autism and self-injurious behavior. Amantadine: profile of use in the developmentally disabled.

American Psychiatric Publishing

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >